26.11.2021 | Melanoma
Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors
verfasst von:
Sonia Cohen, MD, PhD, Genevieve M. Boland, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2022
Einloggen, um Zugang zu erhalten
Excerpt
The clinical success of immune checkpoint blockade for melanoma and other solid tumors has accelerated interest in the application of immuno-oncology across cancer types and stages. Oncolytic virotherapy represents a relatively new class of therapeutic agents that exploit the ability of certain viruses to preferentially replicate in and lyse tumor cells, resulting in an inflammatory response in the tumor microenvironment with the potential to induce or accentuate a systemic antitumor response. …